Trial Profile

A Translational Phase 1B, 2-Part Study to Evaluate Pharmacokinetics, Safety and Pharmacodynamics of Treatment with ATX-304 Na Salt Tablets.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATX 304 (Primary)
Indications Cardiovascular disorders; Metabolic disorders; Obesity; Prediabetic state
Focus Pharmacodynamics; Pharmacokinetics
Sponsors Amplifier Therapeutics; Betagenon

Most Recent Events

03 Jun 2026 According to Cambrian Bio. media release, data from the trial will be presented at the American Diabetes Associations (ADA) 86th Scientific Sessions, taking place June 5-8, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
26 May 2025 Status changed from recruiting to completed.
17 Oct 2023 According to Amplifier Therapeutics, the trial is being conducted in the European Union.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com